Effects of continuous positive airway pressure therapy on systemic inflammation in obstructive sleep apnea: A meta-analysis

Sleep Medicine

Volumn 14, Issue 11, 2013, Pages 1139-1150

  Xie, XiaoMei ^a   Pan, Lei ^b   Ren, DunQiang ^c   Du, ChangJun ^a   Guo, YongZhong ^a  

^a XUZHOU CENTRAL HOSPITAL   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c QINGDAO UNIVERSITY   (China)

Author keywords

C reactive protein; Continuous positive airway pressure; Interleukin 6; Interleukin 8; Meta analysis; Obstructive sleep apnea; Systemic inflammation; Tumor necrosis factor

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATTITUDE TO HEALTH; BLOOD LEVEL; CYTOKINE PRODUCTION; DATA ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; META ANALYSIS; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT ATTITUDE; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; SLEEP DISORDERED BREATHING; SYSTEMIC INFLAMMATION; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

C-REACTIVE PROTEIN; CONTINUOUS POSITIVE AIRWAY PRESSURE; INTERLEUKIN-6; INTERLEUKIN-8; META-ANALYSIS; OBSTRUCTIVE SLEEP APNEA; SYSTEMIC INFLAMMATION; TUMOR NECROSIS FACTOR-Α;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CONTINUOUS POSITIVE AIRWAY PRESSURE; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; OBESITY; SLEEP APNEA, OBSTRUCTIVE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886800726     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2013.07.006     Document Type: Article

References (58)

1. Gopalakrishnan P., Tak T. Obstructive sleep apnea and cardiovascular disease. Cardiol Rev 2011, 19:279-290.
2. Ryan S., Taylor C.T., McNicholas W.T. Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome?. Postgrad Med J 2009, 85:693-698.
3. Almendros I., Farré R., Torres M., Bonsignore M.R., Dalmases M., Ramírez J., et al. Early and mid-term effects of obstructive apneas in myocardial injury and inflammation. Sleep Med 2011, 12:1037-1040.
4. Montesi S., Bajwa E., Malhotra A. Biomarkers of sleep apnea. Chest 2012, 142:239-245.
5. Friedman M., Samuelson C.G., Hamilton C., Fisher M., Kelley K., Joseph N.J., et al. Effect of continuous positive airway pressure on C-reactive protein levels in sleep apnea: a meta-analysis. Otolaryngol Head Neck Surg 2012, 147:423-433. [published online ahead of print June 19, 2012].
6. Guo Y., Pan L., Ren D., Xie X. Impact of continuous positive airway pressure on C-reactive protein in patients with obstructive sleep apnea: a meta-analysis. Sleep Breath 2013, 17:495-503. [published online ahead of print June 5, 2012].
7. Downs S.H., Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998, 52:377-384.
8. Hozo S., Djulbegovic B., Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005, 5:13.
9. Chin K., Nakamura T., Shimizu K., Mishima M., Nakamura T., Miyasaka M., et al. Effects of nasal continuous positive airway pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome. Am J Med 2000, 109:562-567.
10. Ohga E., Tomita T., Wada H., Yamamoto H., Nagase T., Ouchi Y. Effects of obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1. J Appl Physiol 2003, 94:179-184.
11. Yokoe T., Minoguchi K., Matsuo H., Oda N., Minoguchi H., Yoshino G., et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003, 107:1129-1134.
12. Barceló A., Barbé F., Llompart E., Mayoralas L.R., Ladaria A., Bosch M., et al. Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea. Am J Med 2004, 117:118-121.
13. Harsch I., Koebnick C., Wallaschofski H., Schahin S.P., Hahn E.G., Ficker J.H., et al. Resistin levels in patients with obstructive sleep apnoea syndrome - the link to subclinical inflammation?. Med Sci Monit 2004, 10:CR510-CR515. [published online ahead of print August 20, 2004].
14. Minoguchi K., Tazaki T., Yokoe T., Minoguchi H., Watanabe Y., Yamamoto M., et al. Elevated production of tumor necrosis factor-alpha by monocytes in patients with obstructive sleep apnea syndrome. Chest 2004, 126:1473-1479.
15. Kobayashi K., Nishimura Y., Shimada T., Yoshimura S., Funada Y., Satouchi M., et al. Effect of continuous positive airway pressure on soluble CD40 ligand in patients with obstructive sleep apnea syndrome. Chest 2006, 129:632-637.
16. Minoguchi K., Yokoe T., Tanaka A., Ohta S., Hirano T., Yoshino G., et al. Association between lipid peroxidation and inflammation in obstructive sleep apnoea. Eur Respir J 2006, 28:378-385.
17. Ryan S., Taylor C., Mcnicholas W. Predictors of elevated nuclear factor-kappaB-dependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2006, 174:824-830.
18. Drager L., Bortolotto L., Figueiredo A., Krieger E., Lorenzi G. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2007, 176:706-712.
19. Iesato K., Tatsumi K., Saibara T., Nakamura A., Terada J., Tada Y., et al. Decreased lipoprotein lipase in obstructive sleep apnea syndrome. Circ J 2007, 71:1293-1298.
20. Patruno V., Aiolfi S., Costantino G., Murgia R., Selmi C., Malliani A., et al. Fixed and autoadjusting continuous positive airway pressure treatments are not similar in reducing cardiovascular risk factors in patients with obstructive sleep apnea. Chest 2007, 131:1393-1399.
21. Ryan S., Nolan G., Hannigan E., Cunningham S., Taylor C., Mcnicholas W.T. Cardiovascular risk markers in obstructive sleep apnoea syndrome and correlation with obesity. Thorax 2007, 62:509-514.
22. Steiropoulos P., Tsara V., Nena E., Fitili C., Kataropoulou M., Froudarakis M., et al. Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome. Chest 2007, 132:843-851. [published online ahead of print June 15, 2007].
23. Arias M., García-Río F., Alonso-Fernández A., Hernanz A., Hidalgo R., Martínez-Mateo V., et al. CPAP decreases plasma levels of soluble tumour necrosis factor-alpha receptor 1 in obstructive sleep apnoea. Eur Respir J 2008, 32:1009-1015. [published online ahead of print May 28, 2008].
24. Burioka N., Miyata M., Fukuoka Y., Endo M., Shimizu E. Day-night variations of serum interleukin-6 in patients with severe obstructive sleep apnea syndrome before and after continuous positive airway pressure (CPAP). Chronobiol Int 2008, 25:827-834.
25. Dorkova Z., Petrasova D., Molcanyiova A., Popovnakova M., Tkacova R. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest 2008, 134:686-692. [published online ahead of print July 14, 2008].
26. Li Y., Chongsuvivatwong V., Geater A., Liu A. Are biomarker levels a good follow-up tool for evaluating obstructive sleep apnea syndrome treatments?. Respiration 2008, 76:317-323.
27. Sánchez A., Schwartz A., Sánchez P., Fernández J.L., Ramos J., Martín-Herrero F., et al. Hemodynamic and inflammatory markers of sleep apnea-hypopnea syndrome and nocturnal hypoxemia: effects of treatment with nasal continuous positive airway pressure [in Spanish]. Arch Bronconeumol 2008, 44:531-539.
28. Takahashi K., Chin K., Nakamura H., Morita S., Sumi K., Oga T., et al. Plasma thioredoxin, a novel oxidative stress marker, in patients with obstructive sleep apnea before and after nasal continuous positive airway pressure. Antioxid Redox Signal 2008, 10:715-726.
29. Tomiyama H., Okazaki R., Inoue D., Ochiai H., Shiina K., Takata Y., et al. Link between obstructive sleep apnea and increased bone resorption in men. Osteoporos Int 2008, 19:1185-1192. [published online ahead of print January 26, 2008].
30. Vgontzas A., Zoumakis E., Bixler E., Lin H.M., Collins B., Basta M., et al. Selective effects of CPAP on sleep apnoea-associated manifestations. Eur J Clin Invest 2008, 38:585-595.
31. Yamamoto Y., Fujiuchi S., Hiramatsu M., Nishigaki Y., Takeda A., Fujita Y., et al. Resistin is closely related to systemic inflammation in obstructive sleep apnea. Respiration 2008, 76:377-385. [published online ahead of print June 25, 2008].
32. Carneiro G., Togeiro S.M., Ribeiro-Filho F.F., Truksinas E., Ribeiro A.B., Zanella M.T., et al. Continuous positive airway pressure therapy improves hypoadiponectinemia in severe obese men with obstructive sleep apnea without changes in insulin resistance. Metab Syndr Relat Disord 2009, 7:537-542.
33. Drummond M., Winck J., Guimaraes J., Santos A.C., Almeida J., Marques J. Long term effect of autoadjusting positive airway pressure on C-reactive protein and interleukin-6 in men with obstructive sleep apnoea syndrome. Arch Bronconeumol 2009, 45:577-584.
34. Ishida K., Kato M., Kato Y., Yanagihara K., Kinugasa Y., Kotani K., et al. Appropriate use of nasal continuous positive airway pressure decreases elevated C-reactive protein in patients with obstructive sleep apnea. Chest 2009, 136:125-129. [published online ahead of print March 2, 2009].
35. Steiropoulos P., Kotsianidis I., Nena E., Tsara V., Gounari E., Hatzizisi O., et al. Long-term effect of continuous positive airway pressure therapy on inflammation markers of patients with obstructive sleep apnea syndrome. Sleep 2009, 32:537-543.
36. Nena E., Steiropoulos P., Tzouvelekis A., Tsara V., Hatzizisi O., Kyriazis G., et al. Reduction of serum retinol-binding protein-4 levels in nondiabetic obstructive sleep apnea patients under continuous positive airway pressure treatment. Respiration 2010, 80:517-523. [published online ahead of print March 11, 2010].
37. Schiza S., Mermigkis C., Panagiotis P., Bouloukaki I., Kallergis C., Tzanakis N., et al. C-reactive protein evolution in obstructive sleep apnoea patients under CPAP therapy. Eur J Clin Invest 2010, 40:968-975. [published online ahead of print August 19, 2010].
38. Chung S., Yoon I., Lee C., Kim J. The effects of nasal continuous positive airway pressure on vascular functions and serum cardiovascular risk factors in obstructive sleep apnea syndrome. Sleep Breath 2011, 15:71-76.
39. Kasai T., Inoue K., Kumagai T., Kato M., Kawana F., Sagara M., et al. Plasma pentraxin3 and arterial stiffness in men with obstructive sleep apnea. Am J Hypertens 2011, 24:401-407. [published online ahead of print December 30, 2010].
40. Mermigkis C., Bouloukaki I., Mermigkis D., Kallergis E., Mayroudi E., Varouchakis G., et al. CRP evolution pattern in CPAP-treated obstructive sleep apnea patients. Does gender play a role?. Sleep Breath 2012, 16:813-819. [published online ahead of print September 1, 2011].
41. Colish J., Walker J., Elmayergi N., Almutairi S., Alharbi F., Lytwyn M., et al. Obstructive sleep apnea: effects of continuous positive airway pressure on cardiac remodeling as assessed by cardiac biomarkers, echocardiography, and cardiac MRI. Chest 2012, 141:674-681. [published online ahead of print August 11, 2011].
42. Karamanli H., Ozol D., Ugur K.S., Yildirim Z., Armutçu F., Bozkurt B., et al. Influence of CPAP treatment on airway and systemic inflammation in OSAS patients. Sleep Breath 2012, [published online ahead of print September 4, 2012]. 10.1007/s11325-012-0761-8.
43. Oyama J., Yamamoto H., Maeda T., Ito A., Node K., Makino N. Continuous positive airway pressure therapy improves vascular dysfunction and decreases oxidative stress in patients with the metabolic syndrome and obstructive sleep apnea syndrome. Clin Cardiol 2012, 35:231-236.
44. Larkin E., Patel S.R., Goodloe R.J., Li Y., Zhu X., Gray-McGuire C., et al. A candidate gene study of obstructive sleep apnea in European Americans and African Americans. Am J Respir Crit Care Med 2010, 182:947-953. [published online ahead of print June 10, 2010].
45. Bhushan B., Guleria R., Misra A., Luthra K., Vikram N. TNF-alpha gene polymorphism and TNF-alpha levels in obese Asian Indians with obstructive sleep apnea. Respir Med 2009, 103:386-392.
46. Riha R., Brander P., Vennelle M., McArdle N., Kerr S.M., Anderson N.H., et al. Tumour necrosis factor-alpha (-308) gene polymorphism in obstructive sleep apnoea-hypopnoea syndrome. Eur Respir J 2005, 26:673-678.
47. Larkin E., Patel S.R., Zhu X., Tracy R.P., Jenny N.S., Reiner A.P., et al. Study of the relationship between the interleukin-6 gene and obstructive sleep apnea. Clin Transl Sci 2010, 3:337-339.
48. Kent B.D., Ryan S., Mcnicholas W.T. Obstructive sleep apnea and inflammation: relationship to cardiovascular co-morbidity. Respir Physiol Neurobiol 2011, 178:475-481.
49. Hatipoglu U., Rubinstein I. Inflammation and obstructive sleep apnea syndrome pathogenesis: a working hypothesis. Respiration 2003, 70:665-671.
50. Ingram D.G., Matthews C.K. Effect of adenotonsillectomy on c-reactive protein levels in children with obstructive sleep apnea: a meta-analysis. Sleep Med 2013, 14:172-176. [published online ahead of print January 11, 2013].
51. Constantinidis J., Ereliadis S., Angouridakis N., Konstantinidis I., Vital V., Angouridaki C. Cytokine changes after surgical treatment of obstructive sleep apnoea syndrome. Eur Arch Otorhinolaryngol 2008, 265:1275-1279. [published online ahead of print March 4, 2008].
52. Friedman M., Bliznikas D., Vidyasagar R., Woodson B.T., Joseph N.J. Reduction of C-reactive protein with surgical treatment of obstructive sleep apnea hypopnea syndrome. Otolaryngol Head Neck Surg 2006, 135:900-905.
53. Drager L.F., Bortolotto L.A., Lorenzi-Filho G. Effects of CPAP on inflammation in patients with obstructive sleep apnea: is it a matter of time or a matter of marker?. Am J Hypertens 2011, 24:379-380.
54. Tauman R., O'Brien L.M., Gozal D. Hypoxemia and obesity modulate plasma C-reactive protein and interleukin-6 levels in sleep-disordered breathing. Sleep Breath 2007, 11:77-84.
55. Sharma S.K., Mishra H.K., Sharma H., Goel A., Sreenivas V., Gulati V., et al. Obesity, and not obstructive sleep apnea, is responsible for increased serum hs-CRP levels in patients with sleep-disordered breathing in Delhi. Sleep Med 2008, 9:149-156. [published online ahead of print July 16, 2007].
56. Querido J.S., Sheel A.W., Cheema R., Van Eeden S., Mulgrew A.T., Ayas N.T. Effects of 10days of modest intermittent hypoxia on circulating measures of inflammation in healthy humans. Sleep Breath 2012, 16:657-662.
57. Lam J.C., Mak J.C., Ip M.S. Obesity, obstructive sleep apnoea and metabolic syndrome. Respirology 2012, 17:223-236.
58. Kohler M., Ayers L., Pepperell J., Packwood K.L., Ferry B., Crosthwaite N., et al. Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: a randomised controlled trial. Thorax 2009, 64:67-73. [published online ahead of print September 11, 2008].